Abstract : Clinical use of high-intensity focused ultrasound (HIFU) under ultrasound or MR guidance as a non-invasive method for treating tumors is rapidly increasing. Tens of thousands of patients have been treated for uterine fibroid, benign prostate hyperplasia, bone metastases, or prostate cancer. Despite the methods' clinical potential, the liver is a particularly challenging organ for HIFU treatment due to the combined effect of respiratory-induced liver motion, partial blocking by the rib cage, and high perfusion/flow. Several technical and clinical solutions have been developed by various groups during the past 15 years to compensate for these problems. A review of current unmet clinical needs is given here, as well as a consensus from a panel of experts about technical and clinical requirements for upcoming pilot and pivotal studies in order to accelerate the development and adoption of focused ultrasound for the treatment of primary and secondary liver cancer.
http://www.hal.inserm.fr/inserm-00851863
Contributeur : Ed. Bmc
<>
Soumis le : lundi 19 août 2013 - 06:06:16
Dernière modification le : vendredi 31 août 2018 - 09:12:33
Document(s) archivé(s) le : mercredi 20 novembre 2013 - 04:13:56
Jean-Francois Aubry, Kim Pauly, Chrit Moonen, Gail Ter Haar, Mario Ries, et al.. The road to clinical use of high-intensity focused ultrasound for liver cancer: technical and clinical consensus. Journal of Therapeutic Ultrasound, BioMed Central, 2013, 1 (1), pp.13. 〈inserm-00851863〉
